Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 218Triple Negative Breast Neoplasms 17Carcinoma, Intraductal, Noninfiltrating 15Breast Neoplasms, Male 15Inflammatory Breast Neoplasms 13Lung Neoplasms 11Prostatic Neoplasms 10Neoplasms 10Neoplasm Metastasis 10Breast Carcinoma In Situ 9Brain Neoplasms 9Carcinoma, Ductal, Breast 7Melanoma 6Carcinoma, Non-Small-Cell Lung 6Recurrence 5Rectal Neoplasms 4Radiation Injuries 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Dendritic Cell Sarcoma, Interdigitating 4Carcinoma, Renal Cell 4Carcinoma, Lobular 4Burkitt Lymphoma 4Testicular Neoplasms 3

Interventions

Radiotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-Negative Locally Advanced Breast Cancer × Radiotherapy × Breast × Clear all
NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡